Rossini R, Quadri G, Rognoni A, Nardi F, Varbella F, Musumeci G. Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists. Minerva Cardioangiol. 2019;67(5):361–73.

Article  PubMed  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. : 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.

Article  PubMed  Google Scholar 

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr., Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the heart rhythm society in collaboration with the Society of thoracic surgeons. Circulation. 2019;140(2):e125–51.

Article  PubMed  Google Scholar 

Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74.

Article  PubMed  PubMed Central  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

Article  PubMed  Google Scholar 

Köhler C, Tittl L, Marten S, Naue C, Spindler M, Stannek L, Fache K, Beyer-Westendorf J. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. Thromb Res. 2022;215:37–40.

Article  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

Article  PubMed  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

Article  PubMed  Google Scholar 

Ruoff C, Schöchl H, Fritsch G, Voelckel W, Zipperle J, Gratz J, Schmitt F, Oberladstätter D. DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study. Eur J Trauma Emerg Surg 2023.

Lindhoff-Last E, Birschmann I, Kuhn J, Lindau S, Konstantinides S, Grottke O, Nowak-Göttl U, Lucks J, Zydek B, von Heymann C, et al. Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective Observational RADOA-Registry. Thromb Haemost. 2022;122(4):552–9.

Article  PubMed  Google Scholar 

Benz AP, Xu L, Eikelboom JW, Middeldorp S, Milling TJ Jr., Crowther M, Yue P, Conley P, Lu G, Connolly SJ. Andexanet Alfa for specific anticoagulation reversal in patients with Acute bleeding during treatment with Edoxaban. Thromb Haemost. 2022;122(6):998–1005.

Article  PubMed  PubMed Central  Google Scholar 

Pollack CV Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, et al. Idarucizumab for Dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41.

Article  PubMed  Google Scholar 

Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12(9):1428–36.

Article  PubMed  Google Scholar 

Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, et al. Andexanet for factor xa inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med. 2024;390(19):1745–55.

Article  PubMed  Google Scholar 

Heubner L, Mirus M, Vicent O, Güldner A, Tiebel O, Beyer-Westendorf J, Fries D, Spieth PM. Point of care coagulation management in anesthesiology and critical care. Minerva Anestesiol 2022.

Heubner L, Vicent O, Beyer-Westendorf J, Spieth PM. Bleeding management in patients with direct oral anticoagulants. Minerva Anestesiol. 2023;89(7–8):707–15.

PubMed  Google Scholar 

Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S, Schäfer ST. Viscoelastometry for detecting oral anticoagulants. Thromb J. 2021;19(1):18.

Article  PubMed  PubMed Central  Google Scholar 

Oberladstätter D, Voelckel W, Schlimp C, Zipperle J, Ziegler B, Grottke O, Schöchl H. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia. 2021;76(3):373–80.

Article  PubMed  Google Scholar 

Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. 2021 update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(08):1008–20.

Article  PubMed  Google Scholar 

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697–709.

Article  PubMed  Google Scholar 

Calatzis AWM, Leyser H, Hipp Q, Spannagl M. ClotPro – a new generation viscoelastic whole blood coagulation analyzer. Hämostaseologie 2018(p.P013).

Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol. 2008;130(3):446–54.

Article  PubMed  Google Scholar 

Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S, Schafer ST. Viscoelastometry for detecting oral anticoagulants. Thromb J. 2021;19(1):18.

Article  PubMed  PubMed Central  Google Scholar 

Lu G, Conley PB, Leeds JM, Karbarz MJ, Levy GG, Mathur VS, Castillo J, Crowther M, Curnutte JT. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv. 2020;4(4):728–39.

Article  PubMed  PubMed Central  Google Scholar 

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor xa. Nat Med. 2013;19(4):446–51.

Article  PubMed  Google Scholar 

Blackburn M: Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanfa. et al. 2022, 62:144.e141-144.e143.

Orban JE 3rd, Ruckel C, Harlan S. Concomitant andexanet alfa and 4 F-PCC for factor xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2023;233:107908.

Milling TJ Jr., Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, et al. Final study report of Andexanet Alfa for major bleeding with factor xa inhibitors. Circulation. 2023;147(13):1026–38.

Article  PubMed  Google Scholar 

Zipperle J, Schmitt FCF, Schöchl H. Point-of-care, goal-directed management of bleeding in trauma patients. Curr Opin Crit Care. 2023;29(6):702–12.

Article  PubMed  Google Scholar